Patients with high-grade serous ovarian cancer suffer poor prognosis and variable response
to treatment. Known prognostic factors for this disease include homologous recombination …

Summary Cyclin dependent kinase 4/6 (CDK4/6) inhibitors (CDK4/6i) are effective in breast
cancer; however, drug resistance is frequently encountered and poorly understood. We …

Purpose: Genomic methods can identify homologous recombination deficiency (HRD).
Rigorous evaluation of their outcome association to DNA damage response–targeted …

Purpose: Resistance to platinum-based chemotherapy or PARP inhibition in germline
BRCA1 or BRCA2 mutation carriers may occur through somatic reversion mutations or …

Clear cell carcinoma of the endometrium is a rare type of endometrial cancer that is
generally associated with an aggressive clinical behaviour. Here, we sought to define the …

Background Patients with human papillomavirus–related oropharyngeal cancers have
excellent outcomes but experience clinically significant toxicities when treated with standard …

In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like
(APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven …

Alpelisib is a selective inhibitor of phosphoinositide 3-kinase (PI3K) α, shown to improve
outcomes for PIK3CA-mutant, hormone receptor–positive metastatic breast cancers when …

Mutations in ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, are the most
common alterations of the SWI/SNF complex in estrogen-receptor-positive (ER+) breast …

In metastatic cancer, the degree of heterogeneity of the tumor microenvironment (TME) and
its molecular underpinnings remain largely unstudied. To characterize the tumor–immune …